How Substance Use Disorders Are Diagnosed: DSM-5-TR and ICD-11

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

Substance use disorders are diagnosed through a clinical evaluation of a person's relationship with a particular psychoactive substance, the problems associated with its use, and the pattern over time. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), and the World Health Organization's International Classification of Diseases, Eleventh Revision (ICD-11), provide two major diagnostic frameworks. Both recognize that clinically important substance-related problems involve more than how often or how much someone consumes. Their categories, thresholds, and approaches to harmful use differ in ways that matter for individual care, research, and health statistics. American Psychiatric Association, 2022; World Health Organization, 2024.

In DSM-5-TR, a substance use disorder generally requires at least two applicable criteria occurring within the same 12-month period, together with a problematic pattern of use that causes clinically significant impairment or distress. The number of criteria specifies mild, moderate, or severe disorder. ICD-11 distinguishes an episode of harmful use, a harmful pattern of use, and substance dependence. Dependence is organized around impaired control, increasing priority of use, and physiological adaptation, with at least two of three central features required under the relevant time rules. A clinician therefore asks both what happened and which classification is being applied. McNeely et al., 2024; First et al., 2021.

What makes substance use a diagnosable disorder?

The clinical starting point is a history of repeated or otherwise consequential exposure to a specific substance. The clinician examines impaired control, adverse effects on roles and relationships, physical and psychological risks, changes in priorities, and patterns of physiological adaptation. Diagnostic judgment must connect symptoms to the substance and determine whether the observed pattern fulfills a defined diagnostic category. A person can drink or use a drug and remain outside the criteria for a disorder; another person can experience serious drug-related harm without exhibiting a persistent dependence syndrome. World Health Organization, 2024.

Substance use refers to consuming a substance, including use that is prescribed or legal. Risky or hazardous use indicates an elevated likelihood of harm, depending on dose, context, route, age, pregnancy, coexisting illnesses, and other exposures. The everyday phrase substance misuse often describes use outside medical directions or in unsafe situations, but it has variable meanings and should not substitute for a formal diagnosis. A substance use disorder is a clinical classification based on the applicable criteria and overall assessment. The distinction supports early intervention before a disorder emerges and avoids interpreting all exposure as illness. McNeely et al., 2024; Saunders et al., 2019.

Addiction is a widely used clinical and research term for the persistent, compulsive pattern of seeking or using substances despite major negative consequences. It overlaps with substance use disorder, especially more severe manifestations, but it does not name a separate DSM-5-TR symptom count. Physical dependence refers to physiological adaptation that can cause withdrawal when exposure is reduced; tolerance means that the response to a given dose has diminished or a larger amount is needed for a comparable effect. Neither adaptation, in isolation, establishes compulsive use. These differences are crucial when someone receives opioid analgesics or benzodiazepines under appropriate medical supervision. Hasin et al., 2013; American Society of Addiction Medicine, 2025.

DSM-5-TR: the diagnostic logic and threshold

The DSM-5-TR organizes substance use disorder criteria into impaired control, social impairment, risky use, and pharmacological features. A diagnosis is considered when a problematic pattern leads to clinically significant impairment or distress and at least two relevant criteria occur over a 12-month period. The clinician evaluates each criterion in context, checks whether it is attributable to the substance, and applies substance-specific exceptions. These categories support systematic interviewing but do not replace a careful account of timing, functional impact, and the patient's circumstances. American Psychiatric Association, 2022; McNeely et al., 2024.

The eleven DSM-5-TR criteria explained

1. Using larger amounts, or continuing for longer, than intended. This concerns a recurrent mismatch between the person's intended limit and actual consumption.

2. Wanting to cut back or making unsuccessful attempts to control use. The history may include repeated efforts and obstacles to changing the pattern.

3. Spending substantial time obtaining, using, or recovering from the substance. This measures the place of substance use in daily routines and responsibilities.

4. Craving or a strong urge to use. Craving is clinically relevant even when the person is currently avoiding consumption.

5. Recurrent use resulting in failure to meet important responsibilities at work, school, or home. The assessor establishes a meaningful connection between use and impairment.

6. Continuing despite recurrent social or interpersonal problems caused or worsened by use. A disagreement about use alone requires careful contextual interpretation.

7. Reducing or abandoning significant social, occupational, or recreational activities because of use. The criterion assesses lost opportunities and participation.

8. Repeated use in physically hazardous situations. The relevant danger depends on the substance and context, such as driving while impaired.

9. Continuing use despite knowing that it has caused or aggravated a physical or psychological problem. The clinician investigates the person's awareness and the plausibility of the causal relationship.

10. Tolerance, where applicable: needing more for a similar effect or noticing less effect from the same quantity. Expected adaptation during appropriate prescribed treatment is treated differently.

11. Withdrawal, where applicable: characteristic symptoms after reduction or cessation, or using a substance to avoid or relieve those symptoms. Substance-specific definitions and medical-treatment exclusions apply. McNeely et al., 2024; Hasin et al., 2013.

These are paraphrased explanatory descriptions of the diagnostic domains, not a substitute for the substance-specific diagnostic text of DSM-5-TR. The eleven criteria are assessed in relation to the same substance class. Multiple sources of alcohol consumption, for example, are considered together as alcohol exposure; alcohol and opioid problems are evaluated as distinct substance categories. Counting problems across unrelated substances as though they were one disorder can distort diagnostic conclusions. American Psychiatric Association, 2022.

Mild, moderate, and severe in DSM-5-TR

Mild substance use disorder involves two or three applicable criteria during the relevant 12 months. Moderate involves four or five. Severe involves six or more. The classification describes the number of endorsed features; it is not a direct measurement of overdose probability, organ damage, physical withdrawal severity, or the appropriate level of care. Someone meeting two criteria may still face an immediate lethal overdose risk, while another person meeting more criteria may currently have stable medical observations. Clinical risk and diagnostic severity therefore require separate evaluation. McNeely et al., 2024; CDC, 2024.

A threshold is a decision rule and carries clinical tradeoffs. A two-criterion threshold supports recognition of earlier or less extensive problem patterns, yet two symptoms can differ substantially in meaning and consequences. Assessors should confirm that features reflect a coherent clinically significant pattern, use the correct time window, avoid double-counting essentially identical descriptions, and consider competing explanations. The threshold is one component of diagnostic reasoning. Hasin et al., 2013.

What changed from DSM-IV to DSM-5 and DSM-5-TR?

DSM-IV divided substance-related disorders into abuse and dependence categories. DSM-5 consolidated their core problems into a single substance use disorder continuum, removed recurrent legal problems as a diagnostic criterion, added craving, and established the two-criterion threshold and symptom-count severity levels. DSM-5-TR retains the essential substance use disorder framework. These revisions mean that an old diagnosis of abuse or dependence cannot always be translated mechanically into a modern DSM-5-TR severity label without reviewing the underlying history. Hasin et al., 2013; First et al., 2021.

ICD-11: harmful use and dependence are separate clinical concepts

ICD-11 serves international clinical classification and health reporting. The WHO Clinical Descriptions and Diagnostic Requirements explain how professionals apply its categories, while the mortality and morbidity statistical classification supports reporting and coding. Disorders due to substance use are organized by substance class and by the clinical manifestation. ICD-11 preserves distinct ways of identifying clinically significant harm and a more entrenched dependence syndrome. World Health Organization, 2024; Saunders et al., 2019.

Episode of harmful use

An episode of harmful use identifies a single occasion of substance use that has caused clinically significant damage to the person's physical or mental health, or resulted in behavior causing harm to the health of another person, subject to the classification's requirements and exclusions. Such an episode can have medical importance even if repeated impaired control and dependence are absent. The assessment focuses on demonstrable harm and its relationship to that occasion of use. An intoxication event, an injury, and a dependence diagnosis are separate clinical questions. First et al., 2021; World Health Organization, 2024.

Harmful pattern of use

A harmful pattern involves repeated or continuous consumption causing clinically significant physical or mental health damage to the person, or substance-related behavior causing harm to the health of others. For episodic use, the characteristic pattern generally must be evident for at least 12 months; for continuous or nearly daily use, at least one month. A person may meet the harmful-pattern definition without satisfying the requirements for dependence. The diagnosis captures consequential health damage that can deserve intervention before impaired regulation of substance use reaches the dependence threshold. Saunders et al., 2019; First et al., 2021.

Hazardous substance use in ICD-11 is a related health-risk classification rather than a diagnosis within the mental-disorders group. It concerns a pattern that substantially increases the risk of harmful consequences but has not yet produced the damage required for harmful use. This distinction permits preventive action while maintaining a clear boundary between risk, demonstrated harm, and dependence. Saunders et al., 2019.

Substance dependence: three essential features

ICD-11 substance dependence centers on a strong internal drive to use a substance, manifested by impaired regulation. Clinical classification requires at least two of the three central features: impaired control of use; increasing priority given to substance use over health, responsibilities, interests, and other activities, often continuing despite adverse consequences; and physiological features of neuroadaptation, such as tolerance, characteristic withdrawal, or use to prevent withdrawal. The last feature is assessed according to substance-specific physiological knowledge. The key pattern is ordinarily evident over at least 12 months for episodic use, or continuously over at least one month for near-daily use. World Health Organization, 2024; First et al., 2021.

The three features should be evaluated as clinical constructs, with attention to how they manifest in the person's history. A person can experience craving within impaired control, for example, without craving operating as a separate ICD-11 counting item equivalent to the DSM criterion. Physiological adaptation alone supplies only one of the three features. The clinician must establish the required additional feature, overall syndrome, and temporal course before assigning dependence. Saunders et al., 2019.

Substance classes and associated syndromes

ICD-11 includes substance-class categories and substance-associated conditions such as intoxication, withdrawal, and substance-induced mental disorders where applicable. Compared with DSM-5, ICD-11 identifies certain categories more explicitly, including cocaine, synthetic cannabinoids, synthetic cathinones, and MDMA-related groups. The frameworks also differ in terminology and the scope of particular classes. The exact diagnosis should therefore be checked against the named substance and the applicable official classification, rather than inferred from a generic checklist. First et al., 2021; World Health Organization, 2024.

DSM-5-TR and ICD-11 compared in clinical practice

The frameworks agree that meaningful assessment requires substance-specific information, clinically relevant patterns, and an account of impairment or harm. Their principal structural difference is that DSM-5-TR combines multiple types of problems into a single use disorder with a symptom-count gradient, whereas ICD-11 separates harmful episodes, harmful patterns, and dependence. ICD-11 dependence is not simply another name for any DSM-5-TR disorder. The labels describe overlapping but differently defined sets of people. First et al., 2021.

Why the same patient may receive different labels

Consider an adult with recurrent alcohol-related injuries and impaired driving but little evidence of failed attempts to control consumption, loss of competing interests, or physiological dependence. ICD-11 may capture a harmful episode or pattern after its specific criteria are established. A clinician applying DSM-5-TR must independently determine whether the overall problematic pattern and at least two of its criteria are present. Harm by itself cannot be converted automatically into a DSM symptom count. A different person with repeated failed attempts to stop, strong craving, and significant time spent using may reach the DSM threshold even if the ICD harmful-use framework requires further evidence of damage. These are illustrative clinical reasoning patterns, not diagnoses of actual individuals. First et al., 2021.

Similarly, DSM-5-TR mild, moderate, and severe categories do not map one-to-one onto ICD-11 episode, harmful pattern, and dependence categories. ICD-11 dependence typically represents a narrower pattern of disturbed regulation, but discordant cases arise in both directions. Clinical history should be retained when translating across classification systems, and a new assessment may be necessary. Degenhardt et al., 2019.

What research says about agreement

Population-based comparisons of alcohol and cannabis diagnoses found high concordance between the draft ICD-11 criteria and older ICD-10 or DSM-IV diagnoses, while agreement with DSM-5 varied from good to poor depending on the diagnostic pairs. A World Mental Health Surveys analysis covered 12,182 regular alcohol users and 1,788 cannabis users from ten countries. Agreement was particularly weak when researchers compared ICD-11 harmful use with DSM-5 mild disorder, demonstrating that similarly situated categories need not identify the same people. These findings come from retrospective symptom algorithms and the versions assessed in the study, so they should be interpreted alongside later finalized ICD-11 requirements. Degenhardt et al., 2019.

A separate clinical comparison involving alcohol, opioids, cannabis, sedatives, and inhalants also reported varying agreement between DSM-5 and ICD-11 categories. That evidence confirms the importance of study population and substance type, rather than establishing a universal conversion formula. Researchers studying prevalence, outcomes, or treatment response must specify exactly which classification and criteria they applied. Ghosh et al., 2023.

How an actual diagnostic assessment proceeds

Step 1: Establish substance exposure and the time course

Clinicians first identify the substances used, whether prescribed or otherwise obtained, their formulations and routes, their typical and changing frequency, the last exposure, periods of interruption, and use of other substances. They inquire about alcohol, nicotine, cannabis, opioids, stimulants, sedatives, and additional products based on context. Drug names can be uncertain when products are obtained from an unregulated supply; careful assessment should acknowledge possible unrecognized ingredients. The time line is essential because withdrawal, intoxication, hazardous episodes, and an enduring use disorder may occur together or at different times. McNeely et al., 2024.

The assessment also records previous care, medications, medical diagnoses, sleep, pain, cognition, mood, social functioning, trauma-related symptoms, and past episodes of overdose or withdrawal complications. Questions should be asked in a respectful and confidential setting, with appropriate explanations about privacy and mandatory reporting rules when applicable. Accurate disclosure is often improved by nonjudgmental interviewing and opportunities for confidential self-report. McNeely et al., 2024.

Step 2: Use screening tools for case finding, then assess diagnostic features

AUDIT-C is a brief screen for alcohol consumption patterns; DAST-10 is a drug-related screening instrument, and WHO ASSIST covers multiple substance classes and associated risk. These tools can identify people who may benefit from further assessment, and results vary with the population and chosen cutoffs. Their scores do not by themselves establish DSM-5-TR substance use disorder or ICD-11 substance dependence. A positive screen should lead to a clinical conversation about the relevant time period, functional impact, safety, and the formal diagnostic requirements. McNeely et al., 2024; McNeely et al., 2024.

Standardized interviews can improve consistency, particularly in research and complex evaluations, but their output still needs appropriate interpretation. Screening, risk stratification, and formal diagnosis answer related but different questions: who may need evaluation, what harms may occur, and which specific diagnostic category is supported. A high-risk person who does not meet the DSM threshold still deserves harm-reduction advice, monitoring, and appropriate care. McNeely et al., 2024.

Step 3: Check each criterion against real functioning

For DSM-5-TR, the assessor reviews the relevant eleven features and documents their occurrence within the same 12-month window. For ICD-11, the assessor decides whether the evidence supports harmful use, dependence, or another substance-related condition, with the correct time and harm rules. Diagnostic interviewing asks for examples: What changed? How often did it recur? Was the pattern linked to the substance? Were competing demands displaced? Did the person try to reduce use and encounter difficulty? What harm was established and how? First et al., 2021.

Context guards against errors. Missed school due to an unrelated illness cannot automatically be counted as substance-caused impairment. Family conflict alone may reflect multiple dynamics and calls for inquiry into causation. Physical tolerance during a clinically supervised medication course is not evidence of compulsive use on its own. At the same time, respectful assessment does not require the patient to adopt a particular label or agree that a problem exists before the clinician can evaluate objective consequences. Hasin et al., 2013.

Step 4: Evaluate immediate health and psychiatric risks

The assessor evaluates current alertness, breathing, circulation, orientation, psychosis, suicidal thoughts, severe agitation, and possible withdrawal complications. This safety assessment is required regardless of whether a long-term disorder can yet be diagnosed. In an emergency, stabilization and timely referral take precedence over completing a diagnostic checklist. Patients experiencing slow or absent breathing, unresponsiveness, a seizure, severe confusion, serious chest pain, or other signs of life-threatening toxicity require emergency services immediately. CDC, 2024; American Society of Addiction Medicine, 2020.

Step 5: Integrate diagnosis, risk, and care planning

The final clinical formulation identifies the substance-specific disorder or ICD-11 category, relevant course specifiers, acute complications, co-occurring conditions, and practical care needs. It also records diagnostic uncertainty where history is incomplete. A collaborative treatment discussion may encompass medication, behavioral care, management of acute syndromes, harm reduction, and follow-up as appropriate. Determining DSM symptom count and determining the safest setting for care are distinct tasks. McNeely et al., 2024.

Clinical boundaries that change the diagnosis

Prescribed medication, tolerance, and physical dependence

Long-term therapeutic exposure to certain medications can produce tolerance and physical dependence even when the person uses the medication precisely as directed and retains control over treatment. DSM-5-TR specifies that tolerance and withdrawal arising solely during appropriate medical treatment are not counted as criteria for a substance use disorder. The clinician therefore assesses the broader behavior and treatment context, not just the presence of withdrawal symptoms. Separate safety management may be necessary for physical dependence without a diagnosable addiction. McNeely et al., 2024; American Society of Addiction Medicine, 2025.

Prescribed use also cannot be assumed to exclude a disorder. Loss of control, continued use despite clear harm, diversion, obtaining additional substances, and other relevant behaviors can warrant further assessment. The clinician considers the person's diagnosis, indication, adherence, pain or anxiety management, access barriers, and the full pattern before reaching conclusions. Abrupt discontinuation of alcohol or benzodiazepines in a physiologically dependent person may be dangerous and should be managed by qualified clinicians. American Society of Addiction Medicine, 2025.

Intoxication, overdose, and withdrawal

Intoxication is a substance-specific syndrome arising in temporal relation to recent exposure, affecting mental or physical functioning. Overdose is potentially life-threatening toxicity associated with excessive exposure or dangerous combinations; it can occur without an established substance use disorder. Withdrawal is a characteristic physiological and psychological response to reduced exposure after adaptation. A person may experience any of these acute conditions without meeting criteria for a long-term disorder, and may meet long-term criteria without being currently intoxicated or withdrawing. American Psychiatric Association, 2022; World Health Organization, 2024.

Alcohol withdrawal can progress to seizures or delirium, and benzodiazepine withdrawal may cause severe neurological and psychiatric complications, especially after sustained exposure. Abrupt cessation is unsafe for some patients, and clinical withdrawal management may require supervised care. Opioid overdose can suppress breathing and may require immediate emergency response and naloxone where available; naloxone reverses opioid effects but a patient still needs medical evaluation because symptoms can return. Stimulant toxicity can involve arrhythmia, hyperthermia, severe agitation, psychosis, and other emergencies. Clinical triage is driven by current symptoms and exposure, rather than the number of DSM criteria endorsed. American Society of Addiction Medicine, 2020; American Society of Addiction Medicine, 2025; CDC, 2024; ASAM and AAAP, 2024.

Substance-induced psychiatric symptoms and independent disorders

Anxiety, depressed mood, insomnia, hallucinations, suspiciousness, and cognitive changes can appear during intoxication or withdrawal, as part of other mental disorders, or through several interacting processes. A clinician examines onset, prior history, duration beyond substance effects, medication exposure, the substance's known effects, and collateral clinical information where appropriate. The presence of psychosis or panic following substance exposure does not itself establish a separate schizophrenia-spectrum or anxiety diagnosis. A patient can also have both a substance use disorder and an independent mental health disorder requiring coordinated care. McNeely et al., 2024; ASAM and AAAP, 2024.

The evidence on specific comorbid conditions belongs to their own clinical subjects, including Anxiety and Substance Use and Substance-Induced Psychosis. In diagnosis-focused work, their role is to show why timing, source attribution, and longitudinal follow-up matter.

Laboratory tests, urine toxicology, and biomarkers

A biological test may identify recent exposure or a medical complication, but a positive drug result cannot establish impaired control, cravings, persistence despite harm, or a DSM symptom count. Detection windows vary by substance, specimen, assay, frequency of use, and metabolism. Negative results may miss intermittent exposure or substances outside the laboratory panel. Alcohol biomarkers and clinical laboratory measurements can support specific risk and health assessments but do not replace the diagnostic interview. Toxicology should be ordered and interpreted for a clear clinical purpose, with attention to consent and the consequences of misclassification. McNeely et al., 2024.

Applying the frameworks to particular substances

Alcohol

Alcohol use disorder in DSM-5-TR follows the 11-feature framework and the two-criterion threshold. In ICD-11, alcohol-related harmful episodes, harmful patterns, and dependence have distinct roles. Intoxication, withdrawal, liver injury, accidents, and mental health consequences are evaluated on their own clinical terms. Heavy drinking raises risk, while neither a single consumption amount nor a screening score determines the diagnosis. NIAAA, 2025; World Health Organization, 2024.

Opioids

Opioid use disorder assessment examines the pattern of impaired control and consequences while distinguishing illicit or nonmedical use from expected adaptation during appropriate medication treatment. Overdose risk, exposure to fentanyl and other potent opioids, co-use with sedatives, and infectious or medical harms require separate safety review. Medications for opioid use disorder are evidence-based treatments and should be distinguished from short-term management of withdrawal. A person receiving effective treatment may show physiological adaptation while being clinically stable and engaged in recovery. CDC, 2024.

Cannabis

Cannabis-related assessment includes changes in control, functioning, priorities, risk, and, where applicable, tolerance or withdrawal. Interpreting impairment requires attention to potency, route, products, frequency, age, and coexisting mental health symptoms. A diagnosis of cannabis use disorder is different from a finding of recent cannabis exposure or from a separate assessment of psychosis. The two diagnostic systems may identify overlapping yet different groups of people with cannabis-related problems. Degenhardt et al., 2019.

Stimulants, sedatives, and nicotine

For cocaine, methamphetamine, and other stimulants, clinicians consider impaired control, repeated risk, cardiac and psychiatric consequences, and substance-specific withdrawal definitions. Sedatives and benzodiazepines particularly require separation of supervised physiological dependence from disordered use and attention to serious withdrawal risk. Nicotine and tobacco diagnoses involve established dependence and cessation science but may differ in their classification terminology across DSM and ICD. ICD-11 also differentiates several stimulant groups more explicitly than DSM-5-TR. ASAM and AAAP, 2024; First et al., 2021.

Caffeine and contested everyday labels

Caffeine intoxication and withdrawal are recognized clinical phenomena, while caffeine use disorder is not a standard DSM-5-TR substance use disorder diagnosis on the same footing as alcohol or opioid use disorder; the classification has treated the proposed use-disorder construct as an area for additional study. Terms such as phone addiction, social media addiction, and food addiction also require their own diagnostic and evidentiary evaluation. These labels should not be mechanically diagnosed through the substance use disorder checklist. The focus here remains recognized psychoactive-substance disorders and the definitions governing their clinical assessment. Hasin et al., 2013.

Diagnosis across age, pregnancy, and care settings

Young people may present with evolving substance use, developmental vulnerability, school or family difficulties, and a shorter observable history. Assessment should consider age, development, safeguarding, confidentiality, and appropriate involvement of caregivers while applying the relevant clinical criteria. A screening instrument validated in adults may have different performance in adolescents. Diagnostic labels require particular care when the person has limited time for the longitudinal pattern to become clear. McNeely et al., 2024.

During pregnancy and the postpartum period, substance exposure has additional maternal and infant implications, and patients may fear disclosure because of social or legal consequences. A respectful approach explains confidentiality and local reporting obligations, evaluates immediate obstetric and medical risks, and coordinates evidence-based treatment rather than using a positive screen as a final diagnosis. Older adults may experience medication interactions, changes in metabolism, isolation, or functional difficulties that complicate the interpretation of substance-related symptoms. Medical complexity, cognition, and accessibility influence the evaluation in each group. McNeely et al., 2024.

In emergency departments, clinicians first address acute toxicity and stabilization; diagnostic work can continue when the patient can participate reliably. Primary care often identifies risk through screening and an evolving longitudinal relationship. Specialty addiction and psychiatric services can provide expanded assessment of complex patterns, multi-substance exposure, withdrawal risk, and comorbidity. DSM severity and ICD category may inform communication and documentation, while care intensity must also consider safety, medical stability, home environment, preferences, and resources. McNeely et al., 2024; WHO and UNODC, 2020.

Multiple substances and diagnostic attribution

A person can use alcohol, cannabis, opioids, stimulants, and sedatives in overlapping periods. For DSM-5-TR, assess each applicable substance category and its criteria separately instead of summing symptoms indiscriminately across substances. ICD-11 likewise distinguishes the relevant substance classes and their associated harm or dependence patterns. Combined exposure can greatly increase acute risk, especially when opioids are taken with alcohol or other sedatives. Clinical history and available tests may not identify every substance in a mixed supply; uncertainty should be documented rather than concealed. American Psychiatric Association, 2022; World Health Organization, 2024.

Clinicians should clarify whether consequences such as falls, missed work, or medical visits are linked to one substance, multiple substances, the withdrawal state, or an independent condition. A person may meet a formal diagnosis for one substance and have hazardous exposure to another. The final formulation can record multiple coexisting diagnoses along with interaction risks and treatment priorities. This is more precise than attributing every problem to a single broad label.

Remission, course specifiers, and recovery

DSM-5-TR describes early remission when someone previously met full criteria and then has at least three but fewer than twelve months with no applicable substance use disorder criteria other than craving. Sustained remission refers to at least twelve months under that same exception. Specifiers also distinguish certain controlled environments and maintenance-therapy contexts when applicable. These designations refer to diagnostic course, not a complete description of physical health, social functioning, or personal recovery. SAMHSA, 2023.

Recurrence means symptoms or a disorder become active again after improvement or remission. Relapse is used variably in clinical practice and often refers to renewed use or a return to a harmful pattern; its meaning should be stated explicitly. Recovery encompasses change in health, stability, functioning, relationships, autonomy, and goals over time. Some individuals pursue abstinence, while others pursue risk reduction and improved functioning with appropriate clinical care. Diagnostic remission and personal recovery can inform each other without being interchangeable. SAMHSA, 2023; SAMHSA.

An updated diagnosis should reflect the observation period and treatment setting. Improvement during medication treatment can represent substantial clinical progress. Withdrawal symptoms following a medically necessary change in a stable prescription regimen do not automatically indicate return of compulsive use. The evaluation should consider independent functioning, medication continuity, environmental risks, and the person's own experience of recovery.

Reliability, validity, and limitations of diagnostic categories

Diagnostic classifications offer a shared language and support clinical decisions, research inclusion, statistical surveillance, and communication across services. Their accuracy depends on consistent interviewing, correct time windows, patient access to care, reliability of exposure information, and knowledge of the relevant substance. Self-report can be limited by recall, stigma, fear of legal consequences, or fluctuations in insight. Even structured interviews may reach different decisions if definitions or cultural contexts differ. Degenhardt et al., 2019; McNeely et al., 2024.

Diagnostic criteria are operational definitions informed by empirical research and expert consensus. Their thresholds do not demonstrate that all included individuals share an identical biological mechanism, future course, or treatment response. The DSM count model and the ICD dependence model reflect different classification priorities. The evidence supporting their broad clinical usefulness is established; the best crosswalk between categories, the boundary around less severe cases, and variations by substance and culture remain research questions. First et al., 2021; Degenhardt et al., 2019.

Evidence from large surveys supports broad concordance for certain diagnostic comparisons, with important disagreements for others. It does not prove that one system is uniformly superior for every clinical purpose. Evidence from clinical cohorts can offer detailed symptom characterization but may be influenced by referral and severity selection; general-population studies provide different sampling advantages while relying on retrospective interview data. Researchers should report the classification version, diagnostic instrument, substance group, time window, and target population to make results interpretable. Ghosh et al., 2023.

What happens after diagnosis?

A diagnosis supports access to informed discussion, treatment options, and longitudinal care. Clinical planning begins with shared decision-making about priorities, immediate safety, medical conditions, psychiatric symptoms, previous treatment, preferences, and the substance involved. For opioid use disorder, established medication approaches reduce major risks and should be actively considered; alcohol use disorder also has evidence-based pharmacotherapies. Behavioral interventions and continuing recovery supports may be valuable in different combinations, while contingency management has strong evidence for stimulant disorders. The treatment discussion is individual, and managing withdrawal alone does not constitute comprehensive long-term addiction treatment. CDC, 2024; ASAM and AAAP, 2024; WHO and UNODC, 2020.

A person who does not meet a diagnostic threshold can still benefit from preventive advice, review of medication interactions, screening for related conditions, brief motivational counseling, and risk-reduction services. A positive drug test or an alcohol-related injury should not become a stigmatizing lifelong label without a supported diagnosis. Conversely, meeting the diagnostic definition should create opportunities for care rather than exclusion from general medicine, pain treatment, or mental health services. McNeely et al., 2024.

Frequently asked questions

Can someone have a substance use disorder without using every day?

Yes. DSM-5-TR considers the relevant symptoms across a 12-month interval, and some people exhibit recurrent loss of control and consequences during episodic use. ICD-11 includes episodic patterns under its own timing requirements. Frequency helps establish exposure and risk, while diagnostic decisions depend on the full criteria and clinical impact. First et al., 2021.

Is two DSM-5-TR criteria always enough for a diagnosis?

The usual threshold is at least two applicable criteria within twelve months, in the context of a problematic pattern causing clinically significant impairment or distress. The clinician must apply substance-specific rules, assess alternative explanations, and correctly interpret expected responses to prescribed medication. A self-administered checklist is a prompt for professional evaluation, not a diagnosis. McNeely et al., 2024.

Does withdrawal prove addiction?

Withdrawal supports recognition of physiological adaptation. It may occur with some forms of substance use disorder or dependence, but it can also occur during appropriate prescribed treatment. A disorder requires the additional behavioral and clinical features established by the applicable classification. Withdrawal from alcohol or benzodiazepines can be medically dangerous even when no addiction diagnosis has been established. American Society of Addiction Medicine, 2025.

Is ICD-11 dependence the same as severe DSM-5-TR substance use disorder?

The conditions overlap and often describe substantial disturbances in substance regulation, but their operational rules differ. ICD-11 typically requires two of three broad dependence features; DSM-5-TR severe disorder requires at least six of its eleven applicable criteria. Research has documented incomplete agreement, so translation between labels requires reviewing the underlying symptoms and history. Degenhardt et al., 2019.

Can a person have a dangerous overdose without meeting disorder criteria?

Yes. An overdose is an acute toxic event, and severe complications can occur during initial or intermittent exposure, especially with unexpected drug potency or combinations. Urgent treatment is determined by the current emergency, regardless of a later diagnostic decision. If someone is unresponsive or breathing abnormally after suspected opioid exposure, contact emergency medical services immediately and administer naloxone if available according to local emergency guidance. CDC, 2024.

Can a substance use disorder go into remission while treatment continues?

Yes. Diagnostic remission concerns the absence of qualifying symptoms over the specified time, with craving excepted under DSM-5-TR. Clinically indicated medication and ongoing behavioral or recovery support can be part of sustained improvement. Treatment engagement and recovery functioning deserve assessment alongside the formal remission specifier. SAMHSA, 2023.

Which diagnosis should a clinician use: DSM-5-TR or ICD-11?

The choice depends on the national health system, documentation and coding requirements, care setting, and intended research or clinical purpose. Clinicians should apply the official requirements of the system in use and preserve the detailed clinical history when information must be communicated across systems. In the United States, DSM-5-TR is widely used to organize psychiatric diagnosis, while implementation and reporting requirements may involve nationally adopted ICD coding systems. World Health Organization, 2024; McNeely et al., 2024.

Clinical synthesis

The diagnostic question is whether a specific substance has become associated with a defined clinically significant pattern of impaired regulation, consequences, or health damage. DSM-5-TR identifies substance use disorder through a contextualized eleven-criterion framework and classifies symptom-count severity. ICD-11 distinguishes harmful episodes, harmful patterns, and dependence through separate clinical requirements. Both systems require assessment that is broader than a score, urine test, or isolated event. Sound diagnosis includes the substance and temporal history, coexisting medical and psychiatric conditions, acute safety risks, and the individual's treatment goals. The classification communicates a carefully evaluated clinical state; care follows from the whole person and the risks present now.

Related Articles

Cluster Substance Use Disorders and Addiction Recovery — the parent scientific chapter covering the mechanisms, prevention, treatment, harm reduction, and recovery landscape.

Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity — the independent clinical exploration of anxiety and substance-related symptom overlap.

Substance-Induced Psychosis: Causes, Symptoms, and Treatment — differentiation and treatment implications when psychotic symptoms arise in connection with substances.

Schizophrenia and Substance Use Disorders: Dual-Diagnosis Care — coordinated clinical care when schizophrenia and substance use disorders coexist.

Benzodiazepines for Anxiety: Benefits, Risks, Dependence, and Clinical Caution — medication-specific distinctions relevant to prescribed use and physiological dependence.

Substance Use Disorder: Symptoms, Diagnosis, and Treatment — the symptoms, diagnosis, severity, and evidence-based care of substance use disorder.

Substance Use Screening Tools: AUDIT-C, DAST-10, and ASSIST — validated substance use screens, intended populations, scores, and clinical follow-up.

Substance Intoxication vs Withdrawal: Symptoms and Clinical Assessment — acute intoxication, withdrawal syndromes, differential assessment, and triage.

Addiction Severity and Level of Care: How Treatment Needs Are Assessed — severity, multidimensional treatment needs, and clinical care-setting selection.

References

American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Official DSM information.

American Society of Addiction Medicine. (2020). The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. Official guideline.

American Society of Addiction Medicine. (2025). Joint Clinical Practice Guideline on Benzodiazepine Tapering. Official guideline.

American Society of Addiction Medicine and American Academy of Addiction Psychiatry. (2024). The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder. Peer-reviewed guideline.

Centers for Disease Control and Prevention. (2024). Opioid Use Disorder: Treating. Official clinical guidance.

Centers for Disease Control and Prevention. Reversing Opioid Overdose with Naloxone. Official overdose information.

Degenhardt, L., et al. (2019). Concordance between the diagnostic guidelines for alcohol and cannabis use disorders in the draft ICD-11 and other classification systems: Analysis of data from the WHO's World Mental Health Surveys. Addiction. PubMed.

First, M. B., et al. (2021). An organization- and category-level comparison of diagnostic requirements for mental disorders in ICD-11 and DSM-5. World Psychiatry. Full text.

Ghosh, A., et al. (2023). Study on Concordance of ICD-11, ICD-10, and DSM-5 Diagnostic Guidelines for Alcohol and Opioid Use Disorders. Peer-reviewed full text.

Hasin, D. S., et al. (2013). DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationale. American Journal of Psychiatry. Full text.

McNeely, J., Hamilton, L. K., Whitley, S. D., et al. (2024). Substance Use Screening, Risk Assessment, and Use Disorder Diagnosis in Adults. New York State Department of Health AIDS Institute Clinical Guidelines Program. NCBI Bookshelf.

National Institute on Alcohol Abuse and Alcoholism. Alcohol Use Disorder: From Risk to Diagnosis to Recovery. Official clinical resource.

Saunders, J. B., et al. (2019). Aligning the ICD-11 classification of disorders due to substance use with global service needs. Epidemiology and Psychiatric Sciences. Full text.

Substance Abuse and Mental Health Services Administration. (2023). Counseling Approaches To Promote Recovery From Problematic Substance Use and Related Issues, Chapter 1. NCBI Bookshelf.

Substance Abuse and Mental Health Services Administration. About Recovery. Official resource.

World Health Organization. (2024). Clinical Descriptions and Diagnostic Requirements for ICD-11 Mental, Behavioural and Neurodevelopmental Disorders. Official ICD-11 manual.

World Health Organization and United Nations Office on Drugs and Crime. (2020). International Standards for the Treatment of Drug Use Disorders. Official standard.